SOURCE: Lifeline Therapeutics, Inc.

July 11, 2006 10:44 ET

Taglich Brothers Initiates Coverage on Lifeline Therapeutics, Inc.

NEW YORK, NY -- (MARKET WIRE) -- July 11, 2006 -- Taglich Brothers, Inc. announces that it has initiated coverage of Lifeline Therapeutics, Inc. (OTCBB: LFLT).

Lifeline Therapeutics, Inc. (OTCBB: LFLT), headquartered in Englewood, Colorado, is focused on helping people reach their health and wellness goals through science-based solutions to oxidative stress, as well as cellular health. The Company markets its patent-pending dietary supplement called Protandim®, which is supposed to strengthen natural antioxidant defenses, in order to reduce the cell damage known as oxidative stress.

The complete 26-page report is available at

Taglich Brothers, Inc. is full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

* The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned in this report. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned in this report and was not a manager or co-manager of any offering for the company with in the last three years. The company paid for the first year of distribution a fee of $21,000 (USD) on January 2006, and after the first year of publication will pay a monthly monetary fee of $1,750 (USD) to Taglich Brothers, Inc. for the creation and dissemination of research reports.

Contact Information

  • Contact:
    Rick Oh
    Taglich Brothers